Compare Amgen, Inc. (AMGN) vs Harley-Davidson Inc (HOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Harley-Davidson Inc — how do they compare? Amgen, Inc. trades at $413.07 (market cap $225.71B), while Harley-Davidson Inc trades at $27.42 (market cap $2.72B). The key difference: Amgen, Inc. is far larger — about 83× Harley-Davidson Inc's market cap, and Harley-Davidson Inc pays the higher dividend (2.82%). Which is the better fit depends on your goals.
| AMGN | HOG | |
|---|---|---|
Market Cap | $225.71B | $2.72B |
Sector | Health | Consumer Cyclical |
52-Week High | $417.20 | $31.03 |
52-Week Low | $271.18 | $17.19 |
Enterprise Value | $269.02B | $3.13B |
Dividend Yield | 2.42% | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $410.95, up 1.51% today, near its pivot point of $408. The stock shows bullish momentum with strong earnings beats in recent quarters, including Q2 2026 EPS of $6.29 versus $5.62 expected. Revenue reached $36.75B in 2025, with a net income margin of 22.95%. Analyst consensus is bullish with a 58.98% buy rating, though the current price exceeds the consensus target of $394.69. Technical indicators signal an overbought condition with RSI above 75.
Outlook remains positive driven by robust product growth and raised 2026 guidance, but risks include high valuation multiples, significant debt levels, and competitive pressures. The stock's proximity to resistance at $415 suggests near-term consolidation may occur, yet fundamental strength supports long-term upside potential for investors focused on biotech growth.
Harley-Davidson (HOG) trades at $26.01, up 1.21% daily, with a bullish technical signal from moving averages and a neutral RSI. The company reported Q2 2026 EPS of $0.75, beating estimates, and raised full-year guidance. Revenue has declined from $5.8B in 2022 to $4.5B in 2025, with net income margin at 4.78%. Valuation ratios appear attractive with a P/E of 14.45 and P/B of 0.87. Recent news highlights North American sales strength and a strategic shift to U.S. production.
The outlook is cautiously optimistic; earnings beat and raised guidance support upside, but declining revenue and margin pressures pose risks. Analyst consensus is mixed with a $26 price target. Key risks include competitive threats and raw material costs. The stock's valuation discount offers potential if turnaround efforts gain traction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Harley-Davidson Inc
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →
